PharmaTimes May 22, 2024
Jen Brogan

The nanocage technology combines both mRNA and traditional virus-based vaccines to create virus-like efficacious vaccines

A new technology developed by researchers from King’s College London (KCL) could provide a new way of delivering drugs to advance next-generation treatments to prevent and treat a variety of diseases.

Published in the nanotechnology journal Small, the ‘plug and play’ technology could also lead to new therapeutics that act as both a vaccine and a drug, preventing disease and symptoms.

For over two decades, a common protein called ferritin, which manages iron in all organisms, has been used to create vaccines and deliver anticancer drugs, as well as other medicines, to the body.

Until now, scientists have been unable to develop a universal approach...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
STAT+: 3 trends to watch in biotech in 2025
The GLP-1 dilemma persists into 2025
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time

Share This Article